Table 1.

Patient characteristics

		Overall (N=472)		3–5 cycles (N=157)		6–9 cycles (N=315)
		N	%	N	%	N	%	P-value*
Age, years	Median (IQ range)	67 (58–72)		67 (58–72)		67 (58–72)		0.9254
Gender	Male	381	(81.2)	126	(81.3)	255	(81.2)	0.9833
	Female	88	(18.8)	29	(18.7)	59	(18.8)
	NA	3	-	2	-	1	-
ECOG-PS	0	191	(47.8)	57	(47.9)	134	(47.7)	0.6485
	1	173	(43.3)	49	(41.2)	124	(44.1)
	≥2	36	(9.0)	13	(10.9)	23	(8.2)
	NA	72	-	38	-	34	-
WBC count	Median (IQ range)	7.7 (6.2–9.8)		7.3 (6.0–9.3)		7.9 (6.4–10.0)		0.0701
Visceral metastasis (Liver, Lung, Bone)	Yes	207	(43.9)	57	(36.3)	150	(47.6)	0.0196
	No	265	(56.1)	100	(63.7)	165	(52.4)
BMI	Median (IQ range)	27.0 (24.2–29.4)		26.1 (23.9–29.1)		27.1 (24.4–29.9)		0.0810
Ethnicity	Not Hispanic/Latino, White	393	(83.3)	124	(79.0)	269	(85.4)	0.2133
	Not Hispanic/Latino, Black	11	(2.3)	6	(3.8)	5	(1.6)
	Hispanic/Latino	36	(7.6)	12	(7.6)	24	(7.6)
	Other	6	(1.3)	3	(1.9)	3	(1.0)
	Unknown	26	(5.5)	12	(7.6)	14	(4.4)
Prior perioperative chemotherapy	Yes	58	(12.3)	27	(17.2)	31	(9.8)	0.0218
	No	414	(87.7)	130	(82.8)	284	(90.2)
Platinum agent	Cisplatin	338	(71.6)	113	(72.0)	225	(71.4)	0.9014
	Carboplatin	134	(28.4)	44	(28.0)	90	(28.6)
Overall Survival	Median (IQ range)	21.8 months (13.2–52.7)		21.2 months (13.2–59.8)		22.2 months (13.2–48.2)		0.6535
	1-year (95% CI)	78.7% (75.0%−82.6%)		77.9% (71.5%−84.9%)		79.1% (74.6%−83.8%)
	2-year (95% CI)	46.7% (42.1 %−51.9%)		46.1% (37.9%−55.9%)		47.0% (41.5%−53.6%)

Abbreviations: BMI: body mass index; CI: confidence interval; ECOG-PS: Eastern Cooperative Oncology Group-Performance Status; IQ: interquartile: NA: not available; OS: overall survival: WBC: white blood cells.

^*Wilcoxon’s rank sum test was employed for comparing age, WBC, BMI; logrank test for OS; and Pearson’s Chi-square test for the remaining (categorical) variables.